PMID- 30406831 OWN - NLM STAT- MEDLINE DCOM- 20190813 LR - 20200225 IS - 1432-1963 (Electronic) IS - 0172-8113 (Linking) VI - 39 IP - Suppl 2 DP - 2018 Dec TI - [TILGen study-immunological targets in patients with breast cancer : Influence of tumor-infiltrating lymphocytes]. PG - 236-240 LID - 10.1007/s00292-018-0526-7 [doi] AB - BACKGROUND: The interaction of our immune system with breast cancer (BC) cells prompted the investigation of tumor-infiltrating lymphocytes (TILs) and targeted, tumor antigen-specific immunotherapy. OBJECTIVES: Correlation between TILs and pathological complete response (pCR) after neoadjuvant systemic therapy (NACT). Tumor-specific antigens (TSAs) in HER2+ and triple negative BC and establishment of TSA-specific therapies within the interdisciplinary TILGen study. METHODS: Illustration of the TILGen study design. Assessment of TILs and correlation with pCR within this BC study. RESULTS: pCR was achieved in 38.4% (56/146) and associated with estrogen receptor/progesterone receptor negative (ER-/PR-) and HER2+ tumors. Lymphocytic predominant BC (LPBC) was found in 16.4% (24/146), particularly in ER-/PR- (ER-: 27.3% vs. ER+: 9.9%, PR-: 22.3% vs. PR+: 8.2%), large, and poorly differentiated BC. TILs were significantly correlated with pCR in multivariate analysis. In LPBC, pCR was achieved in 66.7%, whereas it was 32.8% in non-LPBC. CONCLUSIONS: First results confirm the influence of the human immune system on the response to NACT in HER2+ and triple negative BC. TSA-specific immunotherapy might improve the outcome in BC patients but there is an urgent need for comprehensive studies to further investigate this issue. FAU - Erber, R AU - Erber R AD - Pathologisches Institut, Universitatsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Krankenhausstrasse 8-10, 91054, Erlangen, Deutschland. Ramona.Erber@uk-erlangen.de. FAU - Hartmann, A AU - Hartmann A AD - Pathologisches Institut, Universitatsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Krankenhausstrasse 8-10, 91054, Erlangen, Deutschland. FAU - Beckmann, M W AU - Beckmann MW AD - Frauenklinik, Universitatsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Deutschland. FAU - Mackensen, A AU - Mackensen A AD - Medizinische Klinik 5, Hamatologie und Internistische Onkologie, Universitatsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Deutschland. FAU - Kremer, A AU - Kremer A AD - Medizinische Klinik 5, Hamatologie und Internistische Onkologie, Universitatsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Deutschland. FAU - Reimann, H AU - Reimann H AD - Medizinische Klinik 5, Hamatologie und Internistische Onkologie, Universitatsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Deutschland. FAU - Hubner, H AU - Hubner H AD - Frauenklinik, Universitatsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Deutschland. FAU - Hein, A AU - Hein A AD - Frauenklinik, Universitatsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Deutschland. FAU - Lux, M P AU - Lux MP AD - Frauenklinik, Universitatsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Deutschland. FAU - Jud, S AU - Jud S AD - Frauenklinik, Universitatsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Deutschland. FAU - Haberle, L AU - Haberle L AD - Frauenklinik, Universitatsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Deutschland. FAU - Gass, P AU - Gass P AD - Frauenklinik, Universitatsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Deutschland. FAU - Volz, B AU - Volz B AD - Frauenklinik, Universitatsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Deutschland. FAU - Schulz-Wendtland, R AU - Schulz-Wendtland R AD - Radiologisches Institut/Gynakologische Radiologie, Universitatsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Deutschland. FAU - Rubner, M AU - Rubner M AD - Frauenklinik, Universitatsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Deutschland. FAU - Fasching, P A AU - Fasching PA AD - Frauenklinik, Universitatsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Erlangen, Deutschland. LA - ger PT - Journal Article PT - Review TT - TILGen-Studie - Immunologische Angriffspunkte bei Patientinnen mit Brustkrebs : Einfluss der tumorinfiltrierenden Lymphozyten. PL - Germany TA - Pathologe JT - Der Pathologe JID - 8006541 RN - 0 (Biomarkers, Tumor) RN - 0 (Receptors, Estrogen) RN - EC 2.7.10.1 (Receptor, ErbB-2) MH - Biomarkers, Tumor MH - *Breast Neoplasms MH - Humans MH - Lymphocytes MH - Lymphocytes, Tumor-Infiltrating MH - Neoadjuvant Therapy MH - Prognosis MH - Receptor, ErbB-2 MH - Receptors, Estrogen MH - Triple Negative Breast Neoplasms OTO - NOTNLM OT - Breast neoplasms OT - Immunotherapy OT - Neoadjuvant therapy OT - Neoplasm antigens OT - Tumor-infiltrating lymphocytes EDAT- 2018/11/09 06:00 MHDA- 2019/08/14 06:00 CRDT- 2018/11/09 06:00 PHST- 2018/11/09 06:00 [pubmed] PHST- 2019/08/14 06:00 [medline] PHST- 2018/11/09 06:00 [entrez] AID - 10.1007/s00292-018-0526-7 [pii] AID - 10.1007/s00292-018-0526-7 [doi] PST - ppublish SO - Pathologe. 2018 Dec;39(Suppl 2):236-240. doi: 10.1007/s00292-018-0526-7.